Seagen (Bothell, WA) — acquired by Pfizer (2023) for $43B. ADC pioneer: Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), Tukysa (tucatinib). Vedotin linker technology. ADC platform licensing to multiple pharma.
12:54:09 AM · Jul 9, 2026
Sign in to reply and join the conversation.